modelLevodopa_1
Extends from Pharmacolibrary.Drugs.ATC.N.N04BA01_1.
Information
| name: | Levodopa_1 | |
| ATC code: | N04BA01_1 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 50 | mg |
| volume of distribution: | 1.9 | L |
| clearance: | 0.9 | L/hr/kg |
| other parameters in model implementation | ||
Levodopa is a precursor of dopamine used primarily in the treatment of Parkinson's disease and parkinsonism. It is usually administered with carbidopa or benserazide to inhibit peripheral metabolism, allowing more levodopa to reach the brain. Levodopa remains an approved drug today and is a mainstay treatment for motor symptoms of Parkinson's disease.
Pharmacokinetics
Healthy adult volunteers, both sexes, after intravenous administration.
References
Neef, C, & van Laar, T (1999). Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clinical pharmacokinetics 37(3) 257–271. DOI:10.2165/00003088-199937030-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10511920
Chan, PL, et al., & Holford, NH (2005). Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. Journal of pharmacokinetics and pharmacodynamics 32(3-4) 307–331. DOI:10.1007/s10928-005-0039-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/16320098
Kubica, A, et al., & Kubica, J (2021). ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial. BMJ open 11(3) e043330–None. DOI:10.1136/bmjopen-2020-043330 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33649058
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)